Investor Presentation

1. OTC : GRPOF
Investor Presentation
May 2, 2017
CSE: TBP
OTC: GRPOF

2. OTC : GRPOF
Forward Looking Statements
This presentation contains certain forward-looking statements that may involve a number of risks and uncertainties.
Actual events or results could differ materially from the expectations and projections of Tetra Bio-Pharma Inc. The information
contained in this presentation has not been approved or disapproved by any Securities Commission in Canada, The Securities and
Exchange Commission in the US or other regulatory body. Except for statements of historical fact relating to the Company, certain
information contained herein constitutes "forward-looking statements". Forward-looking statements are frequently characterized
by words such as "plan", "expect", "project", "intend", "believe", "anticipate" and other similar words, or statements that certain
events or conditions "may" or "will" occur.
Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and
are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially
from those projected in the forward-looking statements. These factors include the inherent risks involved in the development of
botanical based pharmaceuticals or medical devices regulated by Health Canada, the FDA or other international regulatory
agencies, product obsolescence, the uncertainties involved in patent defense and complexities and timelines associated with
product approvals in multiple jurisdictions.
The possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of
financing needed in the future and other factors. Circumstances or management's estimates or opinions could change. The reader
is cautioned not to place undue reliance on forward-looking statements. Except as required by law, we undertake no obligation to
update or revise publicly any forward-looking statements, whether as a result of new information, future event or otherwise, after
the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our
representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the
information in this presentation.
Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise,
to you or any person resulting from the use of the information in this presentation by you or any of your representatives or
from omissions from the information in this presentation.
1

3. OTC : GRPOF
Tetra Bio-Pharma is a bio-pharmaceutical company focused on cannabis
Tetra implements a vertically integrated approach to the development production
and distribution of plant based pharmaceuticals and Bio health products and
supplements with a focus on cannabinoid research and product development
Company Snapshot
▪ Tetra Founded: 2015
▪ CSE (TBP) CAD$0.69
▪ OTCQB (GRPOF) US$0.51
▪ Market Capitalization CAD$79M
▪ Shares Issued 115M
▪ Shares Fully Diluted 131M
▪ Insider Ownership 9.4%
▪ Cash/Equivalent (As of April 28, 2017) CAD$2.8M
▪ Cash Burn Rate/Month CAD$100K
▪ Employees 8
2

4. OTC : GRPOF
Innovations in Pharmaceutical Cannabis &
Nutraceuticals
Pharmaceutical development of
Cannabis-based drug products
Commercialization of Cannabis-
based products for the cosmetic
and supplement markets
License application in system.
Land kept for an interested
partner
3

5. OTC : GRPOF
REPORT: The Cannabis Biotech/Pharma Market Could Surpass $20 Billion by 2020
Viridian Capital Advisors | Wednesday, 02 December 2015 05:43 (EST)
4

6. OTC : GRPOF
THE PHARMACEUTICAL APPROACH TO CANNABIS RESEARCH AND MEDICAL INNOVATION
A Physician’s decision to prescribe a new drug or even a natural health product has to be
based on Evidence-Based Medicine – A legal and ethical requirement
▪Currently, no body of evidence exists to not support the prescription or recommendation of medical
marijuana in any medical condition, including terminal cancer. According to Canadian and USA drug
regulatory agencies, the is no evidence to support the safety and efficacy of marijuana for use in
the treatment of pain or any other indication.
▪TBP product development plan would provide the data necessary for drug regulatory agencies to grant
marketing approval and physicians to prescribe or recommend our products.
▪As cannabis becomes legalised across the globe the medical and scientific community would still
require pharmaceutical consumer drug products developed with proper research , data and protocol.
Insurance companies will only be able to cover the cost of products with Drug Identification Numbers.
▪TBP takes the natural aspects of medical cannabis and applies the science of pharma to develop
products that patients want , doctors want to prescribe and insurance companies will cover.
5

7. OTC : GRPOF
Tetra’s Product Pipeline
Tetra invests significant time and capital into a continuous and sustainable pipe line
of products based on patient needs and driven by scientific R&D
6

8. OTC : GRPOF
Prescription Drugs
▪ PPP001:
▪ Bringing ‘smoked’ marijuana to patients
▪ PPP002:
▪ Adjunct therapy for Breakthrough Cancer Pain
▪ PPP003:
▪ Monotherapy and Combination product – oral administration
▪ Chronic pain, PTSD and other neurologic and psychiatric conditions
▪ PPTGR:
▪ Topical prescription drug for pain management
▪ R&D*
▪ To generate pipeline (create IP and disease-specific treatments)
7

9. OTC : GRPOF
▪ Develop and commercialize Cannabis-derived
products for the consumer market
▪ NSERC funded Partnership with McGill University
▪ Target the USA and Canadian retail markets:
– Generate revenues from product sales in the Food,
dietary supplement and cosmetic markets
– Launch THC and CBD-free extracts of Cannabis in
2017
– Readiness to commercialize THC and CBD
containing products in Canada when legalization is
effective
Partnership #2: Bringing Cannabis-based Products to
Retail Markets
8

10. OTC : GRPOF
▪ Co-Development with acquisition of
technology if successful Phase II in patients
▪ Advantage over approved synthetic THC:
▪ Significant reduction of side effects in patients and
stability at room temperature
▪ Phase I completed:
▪ Demonstrated that safety will be significantly
superior
Partnership #3 (PPP002):
Co-Development – Sustained Release of THC
9

11. OTC : GRPOF
▪ Significantly increase potential to develop
pipeline with strong IP
▪ AgroTek Health will launch a product approved by
NNHPD that induces the CB1 receptor to relieve pain
▪ Replace the PPTGR technology (Topical pain relief)
with this technology (THC and CBD containing topical
drug). Pursue original development plan. IP
protection for technology.
▪ Discovery stage R&D that will lead to new patented
THC and CBD based therapies
Partnership #4:
Investment & Acquisition of R&D Stage Biotech
10

12. OTC : GRPOF
GOAL OF PARTNERSHIP #5 (PPP003)
▪ Co-Development and commercialization of botanical combination
(herb-Cannabis) products:
▪ A partnership defined by a contractual agreement
▪ A Joint Venture (JV) owned 50-50 by 3rd Partnership and TBP
▪ PPP003 is the combination of extracts of –hypnotic herb and
Cannabis oil (extract or further refining of oil)
▪ Two track development:
▪ Cannabis oil as a monotherapy for anxiety and insomnia
▪ Combination product for same indications
▪ Therapeutic targets:
▪ Neurological, mental, psychiatric conditions (e.g., anxiety,
reduced intake of antipsychotics, PTSD, insomnia)
▪ Psychiatrist already proactive using cannabis to lower doses
of antipsychotic drugs or sleep and anxiety drugs (SSRI)
11

13. OTC : GRPOF
Partners
Algorithme Pharma is conducting stage 1 clinical trials of PP001 in
collaboration with Phyto Pain Pharma
McGill University is collaborating with AgroTek and Grow Pros on an
NSERC funded research study to develop consumer products
containing cannabinoids
Aphria is a publicaly traded producer of Medicinal Cannabis
under license from the Canadian Federal Government
Aphria has partnered with Tetra for the production of
Cannabis for use in PPP001
The National Sciences and Engineering Research Council of Canada
connects industry with world-firsts in knowledge and the people
behind them, fueling R&D and leading to firsts in the marketplace.
They have granted TBP subsidiary Grow Pros Cannabis with research
funding related to the development of Consumer products in
collaboration with the university of McGill
12

14. OTC : GRPOF
Cannabis / Medicinal Plant
cultivation and sourcing
▪ Originally applied for ACMPR license in November of 2014,
Currently in stage 3/5
▪ Owns a lease option on 190 acres of agricultural land 45 min north of Ottawa
▪ Signed a co-op agreement with Delta 9 Bio tech to collaborate on
licensing of the facility
▪ Currently examining alternative licensing options for Pharma Development and
sourcing legal supply for use in Pharma and NHP products
13

15. OTC : GRPOF
Competitive Landscape
GW Pharma $GWPH
Market Capitalization: $3.0B USD
GW Pharma has 2 products in its pipe line in stage 1 and stage 3 for epilepsy and MS
Cannabis Science Inc. $CBIS
Market Capitalization $171M USD
Conducts qualitative research on medicinal cannabis in a non pharmaceutical manor.
They have no products in Clinical Testing
INSYS Therapeutics inc- $INSY
Market Capitalization $811M USD
Is a traditional Pharma company that was awarded organ drug status for CBD for treatment of
GBM. They do not have any current clinical trials
Zynerba Pharmaceuticals $ZYNE-
Market Capitalization $278M USD
Developing a synthetic THC transdermal patch as well as a synthetic CBD gel
Cara Therapeutics Inc. $CARA
Market Capitalization $505M USD
R&D on Cannabinoid preceptors . Utilizing synthetic compounds
14

16. OTC : GRPOF
Current Market Valuation ~79M
Value Total
Common Shares 114.5 M
Warrants exp 09/28/18 0.07 - 0.26 8.7 M
Compensation Warrants 0.05 4.0 M
OPTIONS exp 11/5/17 0.05 - 0.18 3.8 M
Average Price of Warrants: $0.20
Average Price of Options: $0.21
Capital Structure (as of April 30, 2017)
15

17. OTC : GRPOF
Financing
▪ Jan 15 - Oct16
Raised ~$1.4M through private placements and executed
warrants at .025-.05-.10-.15
▪ October 2016
Secured 2M equity line of Credit from NYC private equity firm
Alumina Partners
▪ November 2016
Closed a $914,000 financing round at .15 with a
full 12 month warrant at .20
▪ December 2016
▪ $1M investment from Aphria @.20 with a .26 warrant forced exercise at
.45
▪ Closed a $479,100 financing round at .20 with a
full 12 month warrant at .26
16

18. OTC : GRPOF
Leadership
Executive Team
▪ Andre Rancourt – Chief Executive Officer
▪ Guy Chamberland, PHD – Chief Scientific officer
▪ Sabino Di Paola – Chief Financial officer
▪ Ryan Brown – VP, Business Development
▪ Edward Miller – VP, IR & Corporate Communications
▪ Denis Courchesne – VP, Sales
▪ Randy Ringuette, PHD – Medical Researcher
▪ Charles Campbell, PHD – Medical Researcher
Board of Directors
▪ Andre Audet – Chairman/Director
▪ Andre Rancourt – Director
▪ Benoit Chotard – Director
▪ Robert Brouillette – Director
17

19. OTC : GRPOF
Contact
Edward Miller
VP, IR & Corporate Communications
edward@tetrabiopharma.com
www.tetrabiopharma.com
18